Serum interleukin-5 levels correlate with disease activity of Churg-Strauss syndrome in a patient treated with a leucotriene receptor antagonist, pranlukast, and inhaled corticosteroid.
This case report demonstrates that interleukin (IL)-5 levels and eosinophil cationic protein (ECP) correlated well with disease activity of Churg-Strauss syndrome (CSS) in a patient receiving treatment with leucotriene receptor antagonist and inhaled corticosteroid. In addition, ECP was localized in the inflamed tissue. IL-5 levels may thus provide a clue to therapeutic efficacy in patients with CSS using leucotriene receptor antagonists and inhaled corticosteroid.
Taki
H
H
First Department of Internal Medicine, University of Toyama, Sugitani, Toyama, Japan. htaki-tym@umin.ac.jp
Shinoda
K
K
Hounoki
H
H
Ogawa
R
R
Ishizawa
S
S
Sugiyama
E
E
Tobe
K
K
D000328:Adult; D000730:Androstadienes / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002867:Chromones / Q000627:therapeutic use*; D015267:Churg-Strauss Syndrome / Q000097:blood* / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D047150:Eosinophil Cationic Protein / Q000097:blood; D000068298:Fluticasone; D006801:Humans; D015848:Interleukin-5 / Q000097:blood*; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000097:blood; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D002867:Chromones; D015848:Interleukin-5; D020024:Leukotriene Antagonists; D015375:Receptors, Interleukin-2; D000068298:Fluticasone; D047150:Eosinophil Cationic Protein; C047681:pranlukast